Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers

Journal of Clinical Oncology

Volumn 18, Issue 21 SUPPL., 2000, Pages

  Phillips, K A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; PRIORITY JOURNAL; REVIEW;

BRCA2 PROTEIN; BREAST NEOPLASMS; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; IMMUNOPHENOTYPING; NEOPLASM PROTEINS; TRANSCRIPTION FACTORS;

EID: 0034332555     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. The Brca 1 and Brca2 proteins and tumor pathogenesis
2. Hereditary breast cancer: Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage
3. Tumor biological features of BRCA1-induced breast and ovarian cancer
4. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
5. Germ-line BRCA 1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
6. Survival in early-onset breast cancer patients
7. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study
8. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
9. Pathobiologic characteristics of hereditary breast cancer
10. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA 1 and BRCA2 mutations
11. Steroid receptors in hereditary breast carcinomas associated with BRCA 1 or BRCA2 mutations or unknown susceptibility genes
12. BRCA-associated breast cancer in young women
13. Mutations at BRCA1: The medullary breast carcinoma revisited
14. Novel indications for BRCA 1 screening using individual clinical and morphological features
15. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumors
16. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA 1
17. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women
18. Frequency of p53 mutations in breast carcinomas of Ashkenazi Jewish BRCA1 mutation carriers
19. BRCA2 hereditary breast cancer phenotype
20. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability
21. Survival in hereditary breast cancer associated with germline mutations of BRCA2
22. Inherited BRCA2 mutation associated with high grade breast cancer
23. BRCA1 mutations in primary breast and ovarian carcinomas
24. BRCA2 mutations in primary breast and ovarian cancers
25. Low incidence of BRCA2 mutations in breast carcinomas and other cancers
26. Localization of human BRCA1 and its loss in high grade non-inherited breast carcinomas
27. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: A correlation with other biological parameters
28. BRCA1 expression levels predict distant metastasis of sporadic breast cancers
29. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
30. Association of BRCA1 with Rad51 in mitotic and meiotic cells
31. Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51
32. BRCA1, BRCA2, and DNA damage response: Collision or collusion?
33. Partial rescue of BRCA1 early embryonic lethality by p53 or p21 null mutation
34. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of BRCA1, BRCA2, BRCA1/BRCA2, BRCA1/p53, and BRCA2/p53 nullizygous embryos
35. The p53 tumor suppressor gene in breast cancer
36. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
37. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
38. HER-2/neu oncogene protein and prognosis in breast cancer
39. Correlation between c-erbB- 2 amplification and risk of recurrent disease in nodenegative breast cancer
40. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: The South Australian Breast Cancer Study Group
41. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
42. Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted
43. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors
44. Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12-q 13
45. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics
46. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
47. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
48. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2
49. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
50. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation
51. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer
52. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations
53. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?